Custom Checkpoint Antagonistic Antibody Development Service

Antagonistic antibodies mimic ligands that bind to a receptor and prevent receptor activation in the immune system. In medicine, they’re key players in the human body and works against the drug to block the response. As a skillful and reliable partner in the antibody market, Creative Biolabs has gained a high reputation for fine products and custom services by addressing various challenging programs. Especially, we have established a full range of top-selling custom monoclonal antibody service packages for the treatment of varying diseases. And our high-quality checkpoint antagonist antibody production and development services directed at multiple immune markers would bring customer’s project a success.

Overviews

In cancer immunotherapy, a major breakthrough is the discovery of immune checkpoint molecules, which function to effectively inhibit the immune system through diverse mechanisms. The first of such proteins shown to block both T-cell proliferation and interleukin-2 (IL-2) production is cytotoxic T-lymphocyte associated protein 4 (CTLA-4). With that discovery, efforts turn to stop this inhibitory pathway in an attempt to activate dormant T cells against cancer cells. The first antibody targeting CTLA-4, ipilimumab, is quickly invited into clinical trials and has been approved by the FDA for the treatment of metastatic melanoma. Following the success of ipilimumab, many other immune checkpoints are studied as potential targets for inhibition. One such interaction is that of a T-cell receptor, programmed cell death-1 (PD-1), and its ligand found on numerous cancer cells, programmed death-ligand 1 (PD-L1). The exciting area of immune checkpoint inhibitors offers a promising curative option for cancer patients who previously had a dismal prognosis.

Custom Antibody Services at Creative Biolabs

Immune cell function is tightly modulated by co-inhibitory receptors, which block signaling to avoid excessive immune activation, and by co-stimulatory receptors, which are activated in response to exposure to foreign antigens and pathogens. Altogether, these immune checkpoints are essential to control immune cell activity and can be regulated by inhibiting or activating antibodies. Many cancer cells hijack immune checkpoint pathways to prevent clearance of the host immunity. Antagonist antibodies directed against checkpoint co‑inhibitory receptors can reverse immune resistance of some tumors, and a number of candidate agents have been approved for current cancer therapy.

Fig.1 Potential immunomodulatory targets for monoclonal antibody therapy. (Peggs, 2009)

Some antibody drugs for cancers turn off a signaling pathway, while others turn on a signaling pathway. Antibodies are released by the immune system and involved in mediating interactions on the extracellular compartment. They work to help health promotion and immuno-enhancement, as well as treatments based on different types of antibodies, might be curative. At Creative Biolabs, we provide versatile antibody custom services to meet specific process monitoring and regulatory requirements. We're always pleasured to cooperate with clients to develop, qualify, and manufacture a robust antagonistic antibody for preclinical tests and clinical applications. There is a summary as below of several typical immune checkpoint molecules developed or being developing for future antagonistic antibody therapeutics.

IL1 Receptor	CD47	PD-1
PD-L1 (B7-H1)	CTLA-4 (CD152)	LAG-3 (CD223)
TIM-3	TIGIT	VISTA
Trypsin	Factor VIII/Factor IX	LYVE-1
C1 Inhibitor	KIR	TGF-β
IL-10 (CSIF)

To see the detailed introduction of immune checkpoint molecules, click here.

Advantages

Make a time-saving, cost-effective plan before the project start
Multiple animal models for antibody development and production
Hundreds of custom checkpoint antagonist antibodies have been completed successfully
Free of charge if the generated antibody hasn’t been delivered

Through the role as a world-class antibody service provider, Creative Biolabs has favorably accomplished lots of projects regarding custom antibody development services for research and therapeutic applications. Here, we’d like to provide customized checkpoint antagonistic antibody generation and development services for global clients based on our proficient expert teams and advanced technology platforms. For more information, please feel free to contact us.

Reference

Peggs, K.S.; et al. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol. 2009, 157(1): 9-19.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: